Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share for the quarter, Zacks reports. The business had revenue of $1.89 million during the quarter.
Emmaus Life Sciences Stock Up 52.2%
OTCMKTS EMMA opened at $0.04 on Friday. Emmaus Life Sciences has a 52 week low of $0.01 and a 52 week high of $0.09. The business’s fifty day simple moving average is $0.05 and its 200-day simple moving average is $0.02. The firm has a market cap of $2.46 million, a PE ratio of -0.39 and a beta of 11.25.
About Emmaus Life Sciences
Emmaus Life Sciences is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly sickle cell disease. Its main product, Endari, is an oral powder formulation of L-glutamine approved in the United States to reduce acute complications of sickle cell disease in adults and children aged 5 years and older. The U.S. Food and Drug Administration approved Endari in 2017. Emmaus has also pursued development and commercialization opportunities for its products in markets outside the United States.
Read More
- Five stocks we like better than Emmaus Life Sciences
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
